Mandate

Vinge advises Hansa Medical in connection with directed share issue

November 30, 2017 Capital Markets and Public M&A

The board of directors of Hansa Medical has resolved on a directed new issue of ordinary shares, subject to approval by an extraordinary general meeting, whereby Hansa Medical will raise proceeds of approximately SEK 545 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable long-only investors and international sector specialist funds, on the basis of an accelerated bookbuilding process conducted by Evercore, RBC Capital Markets and SEB.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg, Sabina Börjesson and Ramin Baradaran.

Related

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026

Vinge has advised Morrow Bank in connection with its issuances of primary capital instruments (AT1) and tier 2 capital bonds (T2)

The issuances comprised perpetual AT1 bonds of NOK 300 million with a floating coupon of 3-month NIBOR + 425 basis points and a first call date in 2031, as well as subordinated Tier 2 bonds of SEK 200 million with a floating coupon of 3-month STIBOR + 325 basis points and a first call date in 2031. The bonds are intended to be admitted to trading on Nasdaq Stockholm.
July 03, 2026

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026